Pharmaceuticals, Biotechnology and Life Sciences
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Orion Group has announced that Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and Development of the Orion Group and member of the Executive Management Board of the Orion Group will step aside from his current positions as of 21 February 2017.
Eli Lilly has welcomed Carolyn R. Bertozzi, Ph.D., as a new member, of its board, starting on February 10, 2017, joining two committees of the board.
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
Two remaining late-stage clinical trials testing an experimental Alzheimer’s drug from Denmark’s Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
Several leaders of some of the largest pharmaceutical companies have met on Tuesday with the newly elected US president, Donald Trump to discuss industry related topics, agreeing that the talks were positive.
Driven by new products, including Trulicity, Cyramza, Jardiance and Taltz, Lilly’s volume-driven significant growth in 2016.
UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.